Co-Diagnostics, Inc.

NasdaqCM:CODX Stock Report

Market Cap: US$35.9m

Co-Diagnostics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Co-Diagnostics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth16.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated15 Mar 2024

Recent future growth updates

Recent updates

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics spikes on shipments of monkeypox test

Jul 11

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Jul 06
Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Jun 21

Co-Diagnostics: Where's Eikon?

Apr 03

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28
Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28
Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test

Jun 18

Co-Diagnostics: No One-Hit Wonder

Jun 04

This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year

May 18
This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year

These Analysts Just Made A Huge Downgrade To Their Co-Diagnostics, Inc. (NASDAQ:CODX) EPS Forecasts

Mar 30
These Analysts Just Made A Huge Downgrade To Their Co-Diagnostics, Inc. (NASDAQ:CODX) EPS Forecasts

US$22.33: That's What Analysts Think Co-Diagnostics, Inc. (NASDAQ:CODX) Is Worth After Its Latest Results

Mar 27
US$22.33: That's What Analysts Think Co-Diagnostics, Inc. (NASDAQ:CODX) Is Worth After Its Latest Results

Earnings and Revenue Growth Forecasts

NasdaqCM:CODX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20246-31N/AN/A1
12/31/20237-35-23-22N/A
9/30/20235-43-23-21N/A
6/30/20237-38-15-14N/A
3/31/202312-32-8-7N/A
12/31/202234-1457N/A
9/30/202253151415N/A
6/30/202278282526N/A
3/31/2022101403637N/A
12/31/202198374041N/A
9/30/2021105425556N/A
6/30/202196465253N/A
3/31/202193514142N/A
12/31/202075422728N/A
9/30/2020482867N/A
6/30/20202610-3-3N/A
3/31/20202-6-6-5N/A
12/31/20190-6-6-6N/A
9/30/20190-6-5-5N/A
6/30/20190-6-5-5N/A
3/31/20190-6-5-4N/A
12/31/20180-6-4-4N/A
9/30/20180-6-4-4N/A
6/30/20180-8-5-4N/A
3/31/20180-8-4-4N/A
12/31/20170-7-3-3N/A
9/30/20170-6N/A-3N/A
6/30/20170-3N/A-2N/A
3/31/2017N/A-2N/A-1N/A
12/31/2016N/A-2N/A-1N/A
9/30/20160-2N/A-1N/A
12/31/20150-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CODX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if CODX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CODX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CODX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CODX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CODX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.